Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$461K Buy
8,351
+240
+3% +$13K 0.1% 182
2025
Q4
$398K Sell
8,111
-774
-9% -$36.1K 0.09% 184
2025
Q3
$383K Sell
8,885
-1,548
-15% -$60.5K 0.09% 180
2025
Q2
$401K Buy
10,433
+634
+6% +$24.2K 0.08% 206
2025
Q1
$380K Sell
9,799
-360
-4% -$13.2K 0.08% 198
2024
Q4
$344K Sell
10,159
-139
-1% -$5K 0.07% 208
2024
Q3
$421K Sell
10,298
-395
-4% -$16.2K 0.09% 200
2024
Q2
$412K Sell
10,693
-234
-2% -$9.84K 0.1% 196
2024
Q1
$469K Buy
10,927
+246
+2% +$10.1K 0.11% 185
2023
Q4
$396K Buy
10,681
+511
+5% +$18.3K 0.11% 182
2023
Q3
$369K Sell
10,170
-9
-0.1% -$319 0.11% 183
2023
Q2
$363K Sell
10,179
-372
-4% -$13.3K 0.11% 181
2023
Q1
$375K Sell
10,551
-4,091
-28% -$143K 0.13% 161
2022
Q4
$515K Sell
14,642
-11,916
-45% -$397K 0.22% 110
2022
Q3
$781K Sell
26,558
-1,030
-4% -$39K 0.38% 88
2022
Q2
$1.5M Buy
27,588
+1,226
+5% +$67.7K 0.67% 46
2022
Q1
$1.44M Buy
26,362
+10,515
+66% +$571K 0.51% 64
2021
Q4
$873K Buy
15,847
+2,083
+15% +$108K 0.34% 95
2021
Q3
$657K Buy
+13,764
New +$691K 0.26% 104

Other funds holding GSK

Herold Advisors's GSK Position: Q1 2026 in Review

Herold Advisors increased its GSK (GSK) stake by 3% in Q1 2026, buying an estimated $13K and bringing the position to 8,351 shares worth $461K. The position accounts for 0.1% of the portfolio, ranked #182.

Herold Advisors first reported a position in GSK in Q3 2021 and has held it in 19 quarters since. The position peaked at $1.5M in Q2 2022. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Herold Advisors held 8,351 shares of GSK worth $461K as of Q1 2026.
  • Herold Advisors bought 240 GSK shares in Q1 2026, an estimated $13K.
  • GSK made up 0.1% of Herold Advisors's portfolio in Q1 2026, its #182 holding.
  • Herold Advisors first reported a position in GSK in Q3 2021 and has held it in 19 quarters since.
  • Herold Advisors's GSK position peaked at $1.5M in Q2 2022.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Herold Advisors's 13F filing for Q1 2026, filed 15 May 2026.